stockrow
Saturday 7 November 2026
Export IBO’s income statement to Excel — free account
Impact Biomedical Inc.
Impact Biomedical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32,000.00, down 36.0% from fiscal 2022.
- Revenue
- −57.1%
- EPS
- +99.5%
- Free cash flow
- +167.7%
Quarter to June 2026, against a year earlier
4.10
0.30
−6.82%
Follow IBO
Alert me
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
P/E ratio |
0.00 | — | — | 0.00 |
Altman Z-Score |
— | — | — | 0.32 |
P/S ratio |
0.00 | — | — | 552.57 |
P/FCF ratio |
0.00 | — | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
(0.09) | — | — | (2.38) |
P/Operating CF |
(69.76) | — | — | 457.69 |
P/B ratio |
1.02 | — | — | 2.91 |
Price to Tangible BV |
0.00 | — | — | 0.00 |
EV/Sales |
0.00 | — | — | 649.74 |
EV/EBITDA |
0.00 | — | — | 0.00 |
EV/Operating CF |
(13.63) | — | — | (28.19) |
EV/FCF |
(13.50) | — | — | (27.92) |
Quick Ratio |
0.00 | 0.01 | 0.20 | 0.01 |
Current Ratio |
0.01 | 0.03 | 0.25 | 0.35 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.79 | 0.00 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.32 | 0.66 | 0.12 | 0.16 |
Capex/Depreciation |
(0.25) | (0.02) | 0.00 | 0.00 |
Interest Coverage |
(7.37) | (9.07) | (27.00) | (5.40) |
| 0.00% | (14.25%) | (139.68%) | (104.15%) | |
| 0.00% | (9.52%) | (76.11%) | (62.81%) | |
ROIC |
(6.51%) | (8.91%) | (343.08%) | (17.21%) |
Return on Tangible Assets |
69.16% | 34.64% | 337.54% | 1,576.30% |
Average Days of Receivables |
0.00 | 0.00 | — | 57.03 |
Research and Development Expense of Revenue |
2,452.00% | 0.00% | 0.00% | 1,062.50% |
Selling, General and Administrative Expense of Revenue |
650.00% | 0.00% | 0.00% | 2,803.13% |
Intangible Assets out of Total Assets |
0.97 | 0.99 | 0.88 | 0.98 |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 40.63% |
Graham Net Nets |
(0.65) | — | — | (0.03) |
Graham Number |
0.00 | — | — | 0.00 |
Earnings Yield |
(9.19%) | — | — | (267.91%) |
Free Cash Flow Yield |
(7.41%) | — | — | (4.21%) |
Revenue per Share |
0.01 | 0.00 | 0.00 | 0.01 |
Operating CF per Share |
(0.40) | (0.60) | (3.35) | (0.76) |
Capex per Share |
(0.05) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.45) | (0.60) | (3.35) | (0.76) |
Cash per Share |
0.00 | 0.00 | 2.35 | 0.00 |
Shareholders Equity per Share |
5.85 | 5.92 | 8.49 | 6.22 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.85 | 5.92 | 8.49 | 6.22 |
Free Cash Flow |
(2.52) | (2.87) | (2.85) | (1.89) |
Working Capital |
(10.47) | (12.80) | (7.34) | (0.75) |
Capital Expenditures |
(0.28) | (0.02) | — | — |
Net Current Asset Value |
(13.71) | (16.04) | (10.60) | (1.44) |
EV/EBIT |
0.00 | — | — | 0.00 |
Capex to Sales |
5.52 | 0.00 | — | 0.00 |
Price to Operating Income |
0.00 | — | — | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
4.03 | 3.90 | 1,541.88 | 0.00 |
Cash ROIC |
(7.71%) | (10.15%) | (30.90%) | (12.15%) |
Accounts Receivable Turnover |
0.00 | — | — | 0.48 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 1.28 |
Inventory Turnover |
— | — | — | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 298.71 |
Days of Inventory on Hand |
— | — | — | 54.23 |
Average Receivables |
— | — | — | 0.07 |
Average Payables |
— | 0.69 | 0.57 | 0.33 |
Average Assets |
— | 45.57 | 32.46 | 18.85 |
Average Common Equity |
— | 30.44 | 17.69 | 11.37 |
Columns are period end dates · fundamentals updated 26 Oct 2026